Enteric coating is a possible cause of aspirin resistance.

[1]  G. Lip,et al.  The role of aspirin in cardiovascular prevention: implications of aspirin resistance. , 2008, Journal of the American College of Cardiology.

[2]  J. Turgeon,et al.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. , 2007, European heart journal.

[3]  F. Lussana,et al.  Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. , 2007, Haematologica.

[4]  A. Maree,et al.  Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers , 2006, Stroke.

[5]  A. Maree,et al.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. , 2005, Journal of the American College of Cardiology.

[6]  M. Cattaneo.  Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[8]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[9]  J. Dalen.  Aspirin resistance: is it real? Is it clinically significant? , 2007, The American journal of medicine.